Related Experiment Video

Updated: May 29, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA

Rae Sung Chang1, Min Sung Suh, Sunil Kim

  • 1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Daehak-dong, Gwanak-gu, Seoul 151-742, South Korea.

Biomaterials
|September 23, 2011
PubMed

Insights

New nanoparticles effectively co-deliver anticancer drugs and small interfering RNAs (siRNAs) for enhanced cancer therapy. This novel system surpasses existing methods in cellular delivery and tumor growth inhibition, offering a promising combination treatment.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Therapy

Background:

  • Combined modality treatments involving anticancer drugs and small interfering RNAs (siRNAs) represent an emerging strategy in oncology.
  • Developing efficient delivery systems for simultaneous administration of these agents is crucial for therapeutic success.

Purpose of the Study:

  • To develop and evaluate a novel co-delivery system for anticancer drugs and siRNAs using drug-derived cationic nanoparticles.
  • To assess the efficacy of these nanoparticles in cellular delivery, gene silencing, and in vivo tumor growth inhibition.

Main Methods:

  • Mitoxantrone (MTO) was conjugated with palmitoleic acid to form novel lipids (Pal-MTO).
  • Monopalmitoleyl MTO (mono-Pal-MTO) and dipalmitoleyl MTO (di-Pal-MTO) were used to create nanoparticles (md11-Pal-MTO) for siRNA complexation.
  • Cellular delivery efficiency was compared to Lipofectamine 2000 using red fluorescence protein-specific siRNA in B16F10-RFP cells.
  • Antitumor activity was evaluated in vitro using Mcl-1-specific siRNA (siMcl-1) and in vivo via intratumoral administration.

Main Results:

  • Md11-Pal-MTO nanoparticles demonstrated superior siRNA cellular delivery compared to Lipofectamine 2000.
  • Delivery of RFP-specific siRNA resulted in significant reduction of RFP expression at both mRNA and protein levels.
  • In vitro, md11-Pal-MTO mediated delivery of siMcl-1 reduced tumor cell viability by 81%, exceeding Lipofectamine 2000's 68% reduction.
  • Intratumoral administration of siMcl-1 using md11-Pal-MTO nanoparticles inhibited tumor growth by 83%.

Conclusions:

  • Md11-Pal-MTO nanoparticles represent a multifunctional system for the co-delivery of anticancer drugs and siRNAs.
  • This system shows significant potential for enhancing combination therapy efficacy in cancer treatment.
  • The drug-derived nanoparticles offer a promising platform for developing advanced cancer therapeutics.

More Related Videos

Porous Silicon Microparticles for Delivery of siRNA Therapeutics08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...